Qu Biologics Cleared to Proceed with Crohn’s Disease Clinical Trial, DSMC Says

Qu Biologics Cleared to Proceed with Crohn’s Disease Clinical Trial, DSMC Says

biomarker for IBSQu Biologics, Inc., a biotech company that specializes in formulating Site Specific Immunomodulators (SSI) for the restoration of normal immune system function, has just announced that a Data Safety Monitoring Committee (DSMC) has completed a review of one of their pipeline product's safety data from a 30-patient (50% enrollment) clinical trial. The pr

Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *